In this issue of the Journal, Myron Czuczman [1] and colleagues report the results of a phase II trial of nelarabine (compound 506U78) in adult patients with cutaneous T-cell and peripheral T-cell ...
No takes yet. Share an insight, caveat, or question.
Joanne Kurtzberg (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: